Treatment Of Refractory Lung Cancer Research Articles

Chinese expert consensus on refractory lung cancer

The incidence and mortality of lung cancer in China are the highest of all malignant tumors, seriously endangering people's lives and health. Refractory lung cancer is lung cancer that is unresponsive to standard treatment and is difficult to treat, or lung cancer for which a standard treatment has not yet been defined. However, there is still a lack of clear definition and consensus on the treatment of refractory lung cancer. In order to provide guidance for the clinically effective and safe treatment of refractory lung cancer, experts from Chinese Thoracic Society Lung Cancer Study Group have formulated this consensus, on the basis of the actual situation in the field of diagnosis and treatment in our country, with reference to the latest research data, relevant guidelines at home and abroad and experts' clinical practice experience. The consensus makes recommendations on the application of four aspects: refractory small cell lung cancer (SCLC), refractory driver gene-positive non-small cell lung cancer (NSCLC), refractory driver gene-negative NSCLC, and new technological solutions for precision diagnosis and treatment. It also provides references for Chinese clinicians on the use of drugs for refractory lung cancer.

Clinical and Pathological Research Status of Multiple Pulmonary Nodules

With the changes in disease spectrum and the popularization of screening of low-dose spiral CT (CT) in the chest, more and more pulmonary nodules have been detected, most of which are bipulmonary multiple nodules. The existence of multiple pulmonary nodules means that it may be a pathological state of benign and malignant co-existence. The origin and evolution of pulmonary nodules in different histopathological states have a great impact on the choice of treatment methods. In recent years, the rise of immunotherapy has brought a breakthrough in the treatment of refractory lung cancer. However, some patients are still ineffective in immunotherapy, which may be related to the immune microenvironment where nodules are proportioned in different components in different pathological states. This review article mainly predicts the development process of nodules by analyzing the origin of multiple pulmonary nodules and the immune microenvironment of nodules in different pathological conditions, so as to provide guidance for clinical treatment.

Verapamil (VPL) and/or tamoxifen (TAM) combined with chemotherapy in the treatment of refractory lung cancer: Liu XY, Fang H, Fang J. Tumor Clinical College, Beijing Medical University, Beijing. Chin J Clin Oncol 1996;23:229–235

Verapamil (VPL) and/or tamoxifen (TAM) combined with chemotherapy in the treatment of refractory lung cancer: Liu XY, Fang H, Fang J. Tumor Clinical College, Beijing Medical University, Beijing. Chin J Clin Oncol 1996;23:229–235